Reed John's most recent trade in Johnson & Johnson was a trade of 21,721 Employee Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Oct. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2025 | 21,721 | 43,442 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Sale of securities on an exchange or to another person at price $ 192.71 per share. | 17 Oct 2025 | 21,721 | 10,658 (0%) | 0% | 192.7 | 4,185,793 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 157.92 per share. | 17 Oct 2025 | 21,721 | 32,379 (0%) | 0% | 157.9 | 3,430,180 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Sale of securities on an exchange or to another person at price $ 163.55 per share. | 17 Jul 2025 | 19,137 | 10,658 (0%) | 0% | 163.5 | 3,129,830 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 25,255 | 25,255 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 25,255 | 40,797 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.31 per share. | 01 May 2025 | 11,002 | 29,795 (0%) | 0% | 156.3 | 1,719,723 | Common Stock |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 8,540 | 8,540 | - | - | 2025 Performance Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 5,693 | 5,693 | - | - | 2025 Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 15,927 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,350 | 2,698 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 15 Feb 2025 | 385 | 15,542 (0%) | 0% | 156.2 | 60,118 | Common Stock |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 10,279 | 0 | - | - | 2022 Annual Performance Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 10,279 | 24,444 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.36 per share. | 06 Feb 2025 | 4,045 | 20,399 (0%) | 0% | 65.4 | 264,381 | Ordinary Shares |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 2,824 | 13,933 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 2,824 | 0 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.99 per share. | 18 Jan 2025 | 1,986 | 14,165 (0%) | 0% | 74.0 | 146,944 | Ordinary Shares |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 1,491 | 1,491 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 1,491 | 15,424 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 727 | 1,452 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2025 | 727 | 16,151 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 72.66 per share. | 06 Jan 2025 | 4,762 | 11,109 (0%) | 0% | 72.7 | 346,007 | Ordinary Shares |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 26,377 | 0 | - | - | 2021 Program Performance Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 26,377 | 26,377 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.29 per share. | 02 Jan 2025 | 10,506 | 15,871 (0%) | 0% | 72.3 | 759,479 | Ordinary Shares |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 93.96 per share. | 05 Sep 2024 | 6,805 | 0 (0%) | 0% | 94.0 | 639,390 | Ordinary Shares |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 50,510 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 25,255 | 25,561 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 53,510 | - | - | Restricted Share Units | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 22,255 | 22,561 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 11,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 144.59 per share. | 01 May 2024 | 10,984 | 14,577 (0%) | 0% | 144.6 | 1,588,177 | Common Stock |
| Johnson & Johnson | John C. Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 65,163 | 65,163 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | C. John Reed | EVP, Innovative Medicine, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,048 | 4,048 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | Reed David John | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 97.50 per share. | 15 Feb 2024 | 2,700 | 6,805 (0%) | 0% | 97.5 | 263,250 | Ordinary Shares |
| Weatherford Intl PLC - Ordinary Shares - New | David John Reed | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 3,268 | 3,268 | - | - | 2024 Annual Performance Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | John Reed David | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 2,824 | 2,824 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David Reed John | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 2,824 | 9,629 (0%) | 0% | 0 | Ordinary Shares | |
| Weatherford Intl PLC - Ordinary Shares - New | Reed David John | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 2,724 | 2,724 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | David Reed John | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 2,179 | 2,179 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | Reed John David | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.50 per share. | 18 Jan 2024 | 1,615 | 9,505 (0%) | 0% | 94.5 | 152,618 | Ordinary Shares |
| Weatherford Intl PLC - Ordinary Shares - New | John David Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 1,491 | 2,982 | - | - | Restricted Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | John David Reed | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 1,491 | 11,120 (0%) | 0% | 0 | Ordinary Shares | |
| Arhaus Inc (Class A) | Reed John | Director, CEO and Chairman, Ten Percent Owner | 31 Dec 2023 | 769 | 10,769 | - | 9.1 | 7,002 | Class A Common Stock | |
| Arhaus Inc (Class A) | John Reed | Director, CEO and Chairman, Ten Percent Owner | 31 Dec 2023 | 70 | 200 | - | 9.1 | 640 | Class A Common Stock | |
| Arhaus Inc (Class A) | John Reed | Director, CEO and Chairman, Ten Percent Owner | 31 Dec 2023 | 30 | 130 | - | 9.1 | 274 | Class A Common Stock | |
| Arhaus Inc (Class A) | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 6.19 per share. | 13 May 2022 | 40,000 | 41,000 | - | 6.2 | 247,600 | Class A Common Stock |
| Arhaus Inc (Class A) | John Reed | Director, CEO and Chairman, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Jan 2022 | 7,035,433 | 0 | - | - | Class B Common Stock | |
| Arhaus Inc (Class A) | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 10 Dec 2021 | 10,000 | 10,000 | - | 10.5 | 105,000 | Class A Common Stock |
| Arhaus Inc (Class A) | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 10 Dec 2021 | 1,000 | 1,000 | - | 10.5 | 10,500 | Class A Common Stock |
| Arhaus Inc (Class A) | John Reed | Director, CEO and Chairman, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 10 Dec 2021 | 100 | 100 | - | 10.5 | 1,050 | Class A Common Stock |